Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer
Status:
Not yet recruiting
Trial end date:
2030-09-30
Target enrollment:
Participant gender:
Summary
This study is a prospective, open-label, randomized phase 3 clinical trial. It aims to
investigate if the early introduction of intensified chemotherapy (3 months of modified
FOLFIRINOX followed by three months of FOLFIRI) improves the 3-year disease-free survival
rate compared to standard treatment (FOLFOX/CAPOX for an additional three months to complete
six months of standard adjuvant chemotherapy) in patients with stage 2-3 colon cancer in whom
ctDNA MRD in the part 1 study remained positive during adjuvant FOLFOX/CAPOX chemotherapy